Apimeds Pharmaceuticals US, Inc. develops non-opioid, biologic-based therapies for pain management as a clinical-stage biopharmaceutical company. Company news centers on Apitox, also referenced as LT-100, a pure honeybee venom biologic candidate for signs and symptoms of osteoarthritis, with historical approval in South Korea under the Apitoxin name.
Recurring updates also cover U.S. regulatory interactions, clinical-development planning, material agreements, shareholder voting and governance matters, capital-structure disclosures, and operating results. Apimeds has also announced ai² Futures Lab collaborations tied to evaluation of early-stage pharmaceutical assets and biopharma business development projects.
Rhea-AI Summary
Apimeds Pharmaceuticals US (NYSE American: APUS) has announced the pricing of its IPO of 3,375,000 common stock shares at $4.00 per share, expecting to raise $13.5 million in gross proceeds. The company has granted underwriters a 45-day option to purchase up to 506,250 additional shares and warrants for 168,750 shares. Trading will begin on May 9, 2025, under symbol "APUS". D. Boral Capital LLC is the sole book-running manager. The proceeds will fund a Phase III clinical trial in knee osteoarthritis, initiate corporate sponsorship study in multiple sclerosis, manufacture product candidate Apitox (an intradermal bee venom-based toxin), and address working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Apimeds Pharmaceuticals US (APUS)?
Apimeds Pharmaceuticals US (APUS) last closed at $3.25.
What is the market cap of Apimeds Pharmaceuticals US (APUS)?
The market cap of Apimeds Pharmaceuticals US (APUS) is approximately $4.9M.